# Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

> **NCT02463409** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Pseudohypoparathyroidism Type 1a
- Albright Hereditary Osteodystrophy

## Interventions

- **DRUG:** Theophylline

## Key facts

- **NCT ID:** NCT02463409
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463409, "Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02463409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*